{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:45:35Z","timestamp":1783377935475,"version":"3.54.6"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The US Preventive Services Task Force guidelines advise against prostate-specific antigen (PSA) screening for prostate cancer in males older than 69 years due to the risk of false-positive results and overdiagnosis of indolent disease. However, this low-value PSA screening in males aged 70 years or older remains common.<\/jats:p><\/jats:sec>Objective<\/jats:title>To characterize the factors associated with low-value PSA screening in males 70 years or older.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This survey study used data from the 2020 Behavioral Risk Factor Surveillance System (BRFSS), a nationwide annual survey conducted by the Centers for Disease Control and Prevention that collects information via telephone from more than 400\u202f000 US adults on behavioral risk factors, chronic illnesses, and use of preventive services. The final cohort comprised male respondents to the 2020 BRFSS survey who were categorized into the following age groups: 70 to 74 years, 75 to 79 years, or 80 years or older. Males with a former or current prostate cancer diagnosis were excluded.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The outcomes were recent PSA screening rates and factors associated with low-value PSA screening. Recent screening was defined as PSA testing within the past 2 years. Weighted multivariable logistic regressions and 2-sided significance tests were used to characterize factors associated with recent screening.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 32\u202f306 males. Most of these males (87.6%) were White individuals, whereas 1.1% were American Indian, 1.2% were Asian, 4.3% were Black, and 3.4% were Hispanic individuals. Within this cohort, 42.8% of respondents were aged 70 to 74 years, 28.4% were aged 75 to 79 years, and 28.9% were 80 years or older. The recent PSA screening rates were 55.3% for males in the 70-to-74-year age group, 52.1% in the 75-to-79-year age group, and 39.4% in the 80-year-or-older group. Among all racial groups, non-Hispanic White males had the highest screening rate (50.7%), and non-Hispanic American Indian males had the lowest screening rate (32.0%). Screening increased with higher educational level and annual income. Married respondents were screened more than unmarried males. In a multivariable regression model, discussing PSA testing advantages with a clinician (odds ratio [OR], 9.09; 95% CI, 7.60-11.40; P<\/jats:italic>\u2009&amp;lt;\u2009.001) was associated with increased recent screening, whereas discussing PSA testing disadvantages had no association with screening (OR, 0.95; 95% CI, 0.77-1.17; P<\/jats:italic>\u2009=\u2009.60). Other factors associated with a higher screening rate included having a primary care physician, a post\u2013high school educational level, and income of more than $25\u202f000 per year.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Results of this survey study suggest that older male respondents to the 2020 BRFSS survey were overscreened for prostate cancer despite the age cutoff for PSA screening recommended in national guidelines. Discussing the benefits of PSA testing with a clinician was associated with increased screening, underscoring the potential of clinician-level interventions to reduce overscreening in older males.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.7504","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:02:09Z","timestamp":1681225329000},"page":"e237504","source":"Crossref","is-referenced-by-count":30,"title":["Low-Value Prostate-Specific Antigen Screening in Older Males"],"prefix":"10.1001","volume":"6","author":[{"given":"Sandhya","family":"Kalavacherla","sequence":"first","affiliation":[{"name":"University of California San Diego School of Medicine, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Riviere","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Javier-DesLoges","sequence":"additional","affiliation":[{"name":"Department of Urology, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Banegas","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S.","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"issue":"2","key":"zoi230247r1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer.","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"7","key":"zoi230247r2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials.","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi230247r3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/JCO.2010.30.5979","article-title":"Comorbidity and mortality results from a randomized prostate cancer screening trial.","volume":"29","author":"Crawford","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi230247r4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study.","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi230247r5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.","volume":"95","author":"Draisma","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"zoi230247r6","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"zoi230247r10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s40615-014-0061-z","article-title":"The relationship between education and prostate-specific antigen testing among urban African American Medicare beneficiaries.","volume":"2","author":"Hararah","year":"2015","journal-title":"J Racial Ethn Health Disparities"},{"issue":"5","key":"zoi230247r11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/21681805.2019.1681503","article-title":"Educational level and first-time PSA testing in general practice.","volume":"53","author":"Lerhmann-Lerche","year":"2019","journal-title":"Scand J Urol"},{"key":"zoi230247r12","doi-asserted-by":"publisher","DOI":"10.5888\/pcd12.150088","article-title":"Prostate cancer screening among American Indians and Alaska Natives: the Health and Retirement Survey, 1996-2008.","volume":"12","author":"Goins","year":"2015","journal-title":"Prev Chronic Dis"},{"key":"zoi230247r13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1471-2296-15-121","article-title":"Prostate specific antigen testing is associated with men\u2019s psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study.","volume":"15","author":"Flahavan","year":"2014","journal-title":"BMC Fam Pract"},{"key":"zoi230247r14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.canep.2016.09.010","article-title":"Lifestyle factors and prostate-specific antigen (PSA) testing in UK Biobank: implications for epidemiological research.","volume":"45","author":"Littlejohns","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"Suppl 2","key":"zoi230247r15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/00333549141291S206","article-title":"The social determinants of health: it\u2019s time to consider the causes of the causes.","volume":"129","author":"Braveman","year":"2014","journal-title":"Public Health Rep"},{"key":"zoi230247r16","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8646314","article-title":"Prostate-specific antigen screening according to health professional counseling and age in the United States.","volume":"2022","author":"Merrill","year":"2022","journal-title":"Prostate Cancer"},{"key":"zoi230247r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.033","article-title":"Smoking and risk of prostate cancer and prostate cancer death: a pooled study.","author":"Jochems","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"zoi230247r18","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djaa171","article-title":"Racial and ethnic variation in PSA testing and prostate cancer incidence following the 2012 USPSTF recommendation.","volume":"113","author":"Kensler","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"zoi230247r22","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1001\/jama.296.19.2336","article-title":"PSA screening among elderly men with limited life expectancies.","volume":"296","author":"Walter","year":"2006","journal-title":"JAMA"},{"issue":"40","key":"zoi230247r23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017451","article-title":"Factors associated with false negative and false positive results of prostate-specific antigen (PSA) and the impact on patient health: cohort study protocol.","volume":"98","author":"Bernal-Soriano","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"zoi230247r24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA guideline.","volume":"190","author":"Carter","year":"2013","journal-title":"J Urol"},{"key":"zoi230247r9","volume-title":"Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys","author":"American Association for Public Opinion Research","year":"2016","edition":"9th ed"},{"key":"zoi230247r19","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2020"},{"key":"zoi230247r7","unstructured":"Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention. 2020 BRFSS Data. Accessed March 12, 2023. https:\/\/www.cdc.gov\/brfss\/annual_data\/annual_2020.html"},{"key":"zoi230247r8","unstructured":"Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention. Overview: BRFSS 2020. July 7, 2021. Accessed March 12, 2023. https:\/\/www.cdc.gov\/brfss\/annual_data\/2020\/pdf\/overview-2020-508.pdf"},{"key":"zoi230247r20","unstructured":"Wickham? H, Miller? E. Package \u201chaven\u201d: import and export \u2018SPSS\u2019, \u2018STATA\u2019 and \u2018SAS\u2019 files. 2021. Accessed March 12, 2023. https:\/\/cran.r-project.org\/web\/packages\/haven\/haven.pdf"},{"key":"zoi230247r21","unstructured":"Lumley? T. Package \u201csurvey\u201d: analysis of complex survey samples. R package version 4.0. 2020. Accessed March 12, 2023. https:\/\/cran.r-project.org\/web\/packages\/survey\/survey.pdf"},{"key":"zoi230247r25","unstructured":"American Cancer Society. American Cancer Society Recommendations for Prostate Cancer Early Detection. April 23, 2021. Accessed March 12, 2023. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/acs-recommendations.html"},{"key":"zoi230247r26","unstructured":"Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention. 2020 Summary Data Quality Report. August 2, 2021. Accessed March 12, 2023. https:\/\/www.cdc.gov\/brfss\/annual_data\/2020\/pdf\/2020-sdqr-508.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803670\/kalavacherla_2023_oi_230247_1680623471.58396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:02:16Z","timestamp":1681225336000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7504","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}